Trials / Unknown
UnknownNCT04445779
Q10 Preloading Before Cardiac Surgery for Kidney Failure Reduction
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Clinical Hospital Center, Split · Academic / Other
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
Coenzyme Q10 (CoQ10) is an essential molecule in human body. It acts as an antioxidant, a co-factor for energy conversion in mitochondria and has anti-inflammatory effects capable of improving endothelial function. Our goal is to investigate whether CoQ10 is capable to reduce the incidence of acute kidney injury/failure following cardiac surgery. Cardiac surgery is major risk factor for acute kidney injury/failure (AKI/F).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Coenzyme Q10 | Patients will receive per-orally 10 mg/kg of body weight of coenzyme Q10 in form of Myokinon (PharmaNord, Denmark) in three divided doses. They will receive therapy for at least 10 days before surgical procedure. |
Timeline
- Start date
- 2020-07-15
- Primary completion
- 2021-09-01
- Completion
- 2021-12-01
- First posted
- 2020-06-24
- Last updated
- 2020-07-16
Locations
1 site across 1 country: Croatia
Source: ClinicalTrials.gov record NCT04445779. Inclusion in this directory is not an endorsement.